REFERENCES
- Yonish-Rouach E, Resnitzky D, Lotem J, et al, Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991; 352: 345–7. [PUBMED], [INFOTRIEVE]
- Kastan M B, Onyekwere O, Sidransky D, et al, Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51: 6304–11. [PUBMED], [INFOTRIEVE]
- Hollstein M, Sidransky D, Vogelstein B, et al, p53 mutations in human cancers. Science. 1991; 253: 49–53. [PUBMED], [INFOTRIEVE]
- Olivier M, Eeles R, Hollstein M, et al, The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat. 2002; 19: 607–14. [PUBMED], [INFOTRIEVE]
- Hainaut P, Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res. 2000; 77: 81–137. [PUBMED], [INFOTRIEVE]
- Donehower L A, Harvey M, Slagle B L, et al, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356: 215–21. [PUBMED], [INFOTRIEVE]
- Yang A, Kaghad M, Wang Y, et al, p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998; 2: 305–16. [PUBMED], [INFOTRIEVE]
- Kaghad M, Bonnet H, Yang A, et al, Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997; 90: 809–19. [PUBMED], [INFOTRIEVE]
- Levrero M, de, Laurenzi V, Costanzo A, et al, The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci. 2000; 113: 1661–70. [PUBMED], [INFOTRIEVE]
- Lane D P. Cancer. p53, guardian of the genome. Nature. 1992; 358: 15–6. [PUBMED], [INFOTRIEVE]
- Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol. 1986; 6: 1379–85. [PUBMED], [INFOTRIEVE]
- el, Deiry W S, Kern S E, Pietenpol J A, et al, Definition of a consensus binding site for p53. Nat Genet. 1992; 1: 45–9. [PUBMED], [INFOTRIEVE]
- Cho Y, Gorina S, Jeffrey P D, et al, Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science. 1994; 265: 346–55. [PUBMED], [INFOTRIEVE]
- Hainaut P, Milner J. A structural role for metal ions in the “wild-type” conformation of the tumor suppressor protein p53. Cancer Res. 1993; 53: 1739–42. [PUBMED], [INFOTRIEVE]
- Momand J, Zambetti G P, Olson D C, et al, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69: 1237–45. [PUBMED], [INFOTRIEVE]
- Oliner J D, Kinzler K W, Meltzer P S, et al, Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358: 80–3. [PUBMED], [INFOTRIEVE]
- Kubbutat M H, Jones S N, Vousden K H. Regulation of p53 stability by Mdm2. Nature. 1997; 387: 299–303. [PUBMED], [INFOTRIEVE]
- Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999; 274: 36031–4. [PUBMED], [INFOTRIEVE]
- Vogelstein B, Lane D, Levine A J. Surfing the p53 network. Nature. 2000; 408: 307–10. [PUBMED], [INFOTRIEVE]
- Pluquet O, Hainaut P.. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 2001; 174: 1–15. [PUBMED], [INFOTRIEVE]
- Siliciano J D, Canman C E, Taya Y, et al, DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997; 11: 3471–81. [PUBMED], [INFOTRIEVE]
- Quelle D E, Zindy F, Ashmun R A, et al, Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995; 83: 993–1000. [PUBMED], [INFOTRIEVE]
- Weber J D, Taylor L J, Roussel M F, et al, Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999; 1: 20–6. [PUBMED], [INFOTRIEVE]
- Hussain S P, Hofseth L J, Harris C C. Radical causes of cancer. Nat Rev Cancer. 2003; 3: 276–85. [PUBMED], [INFOTRIEVE]
- Tokino T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev Oncol Hematol. 2000; 33: 1–6. [PUBMED], [INFOTRIEVE]
- Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ. 2003; 10: 431–42. [PUBMED], [INFOTRIEVE]
- Wilson J W, Pritchard D M, Hickman J A, et al, Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: Apoptosis and cell cycle arrest. Am J Pathol. 1998; 153: 899–909. [PUBMED], [INFOTRIEVE]
- Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: Searching for clues of environmental carcinogenesis. Semin Cancer Biol. 2001; 11: 353–60. [PUBMED], [INFOTRIEVE]
- Scheffner M, Werness B A, Huibregtse J M, et al, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63: 1129–36. [PUBMED], [INFOTRIEVE]
- Hanahan D, Weinberg R A. The hallmarks of cancer. Cell. 2000; 100: 57–70. [PUBMED], [INFOTRIEVE]
- Lin J, Chen J, Elenbaas B, et al, Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994; 8: 1235–46. [PUBMED], [INFOTRIEVE]
- Freeman J, Schmidt S, Scharer E, et al, Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J. 1994; 13: 5393–400. [PUBMED], [INFOTRIEVE]
- Strauss B S. Role in tumorigenesis of silent mutations in the TP53 gene. Mutat Res. 2000; 457: 93–104. [PUBMED], [INFOTRIEVE]
- Resnick M A, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA. 2003; 100: 9934–9. [PUBMED], [INFOTRIEVE]
- Inga A, Storici F, Darden T A, et al, Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol. 2002; 22: 8612–25. [PUBMED], [INFOTRIEVE]
- Flaman J M, Robert V, Lenglet S, et al, Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene. 1998; 16: 1369–72. [PUBMED], [INFOTRIEVE]
- Ludwig R L, Bates S, Vousden K H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol. 1996; 16: 4952–60. [PUBMED], [INFOTRIEVE]
- Smith P D, Crossland S, Parker G, et al, Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene. 1999; 18: 2451–9. [PUBMED], [INFOTRIEVE]
- Kato S, Han S Y, Liu W, et al, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 2003; 100: 8424–9. [PUBMED], [INFOTRIEVE]
- Gannon J V, Greaves R, Iggo R, et al, Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9: 1595–602. [PUBMED], [INFOTRIEVE]
- Brachmann R K, Vidal M, Boeke J D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA. 1996; 93: 4091–5. [PUBMED], [INFOTRIEVE]
- Cadwell C, Zambetti G P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 2001; 277: 15–30. [PUBMED], [INFOTRIEVE]
- Gaiddon C, Lokshin M, Ahn J, et al, A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001; 21: 1874–87. [PUBMED], [INFOTRIEVE]
- Strano S, Munarriz E, Rossi M, et al, Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem. 2000; 275: 29503–12. [PUBMED], [INFOTRIEVE]
- Strano S, Fontemaggi G, Costanzo A, et al, Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem. 2002; 277: 18817–26. [PUBMED], [INFOTRIEVE]
- Cai D W, Mukhopadhyay T, Liu Y, et al, Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther. 1993; 4: 617–24. [PUBMED], [INFOTRIEVE]
- Fujiwara T, Grimm E A, Mukhopadhyay T, et al, A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 1993; 53: 4129–33. [PUBMED], [INFOTRIEVE]
- Runnebaum I B, Wang S, Kreienberg R. Retrovirally mediated wild-type p53 restores S-phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53. J Cell Biochem. 1995; 59: 537–44. [PUBMED], [INFOTRIEVE]
- Roth J A, Nguyen D, Lawrence D D, et al, Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996; 2: 985–91. [PUBMED], [INFOTRIEVE]
- Putzer B M, Bramson J L, Addison C L, et al, Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther. 1998; 9: 707–18. [PUBMED], [INFOTRIEVE]
- Inoue A, Narumi K, Matsubara N, et al, Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 2000; 157: 105–12. [PUBMED], [INFOTRIEVE]
- Giuliano M, Catalano A, Strizzi L, et al, Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med. 2000; 5: 591–6. [PUBMED], [INFOTRIEVE]
- Eastham J A, Grafton W, Martin C M, et al, Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol. 2000; 164: 814–9. [PUBMED], [INFOTRIEVE]
- Dummer R, Bergh J, Karlsson Y, et al, Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther. 2000; 7: 1069–76. [PUBMED], [INFOTRIEVE]
- Schuler M, Rochlitz C, Horowitz J A, et al, A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther. 1998; 9: 2075–82. [PUBMED], [INFOTRIEVE]
- Clayman G L, el, Naggar A K, Lippman S M, et al, Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16: 2221–32. [PUBMED], [INFOTRIEVE]
- Swisher S G, Roth J A, Nemunaitis J, et al, Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91: 763–71. [PUBMED], [INFOTRIEVE]
- Swisher S G, Roth J A, Komaki R, et al, Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003; 9: 93–101. [PUBMED], [INFOTRIEVE]
- Lang F F, Bruner J M, Fuller G N, et al, Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol. 2003; 21: 2508–18. [PUBMED], [INFOTRIEVE]
- Wen S F, Mahavni V, Quijano E, et al, Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003; 10: 224–38. [PUBMED], [INFOTRIEVE]
- Pagliaro L C, Keyhani A, Williams D, et al, Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J Clin Oncol. 2003; 21: 2247–53. [PUBMED], [INFOTRIEVE]
- Gridley D S, Andres M L, Li J, et al, Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol. 1998; 13: 1093–8. [PUBMED], [INFOTRIEVE]
- Timiryasova T M, Li J, Chen B, et al, Antitumor effect of vaccinia virus in glioma model. Oncol Res. 1999; 11: 133–44. [PUBMED], [INFOTRIEVE]
- Timiryasova T M, Gridley D S, Chen B, et al, Radiation enhances the anti-tumor effects of vaccinia-p53 gene therapy in glioma. Technol Cancer Res Treat. 2003; 2: 223–35. [PUBMED], [INFOTRIEVE]
- Chen B, Timiryasova T M, Andres M L, et al, Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther. 2000; 7: 1437–47. [PUBMED], [INFOTRIEVE]
- Conseiller E, Debussche L, Landais D, et al, CTS1: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest. 1998; 101: 120–7. [PUBMED], [INFOTRIEVE]
- Bougeret C, Virone-Oddos A, Adeline E, et al, Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2. Cancer Gene Ther. 2000; 7: 789–98. [PUBMED], [INFOTRIEVE]
- Naumann U, Kugler S, Wolburg H, et al, Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res. 2001; 61: 5833–42. [PUBMED], [INFOTRIEVE]
- Habib N A, Ding S F, el, Masry R, et al, Preliminary report: The short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev. 1996; 20: 103–7. [PUBMED], [INFOTRIEVE]
- Lesoon-Wood L A, Kim W H, Kleinman H K, et al, Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther. 1995; 6: 395–405. [PUBMED], [INFOTRIEVE]
- Xu L, Tang W H, Huang C C, et al, Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med. 2001; 7: 723–34. [PUBMED], [INFOTRIEVE]
- Xu L, Huang C C, Huang W, et al, Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002; 1: 337–46. [PUBMED], [INFOTRIEVE]
- Matsubara H, Maeda T, Gunji Y, et al, Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells. Int J Oncol. 2001; 18: 825–9. [PUBMED], [INFOTRIEVE]
- Takenobu T, Tomizawa K, Matsushita M, et al, Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther. 2002; 1: 1043–9. [PUBMED], [INFOTRIEVE]
- Teodoro J G, Shore G C, Branton P E. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene. 1995; 11: 467–74. [PUBMED], [INFOTRIEVE]
- Bischoff J R, Kirn D H, Williams A, et al, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996; 274: 373–6. [PUBMED], [INFOTRIEVE]
- Heise C, Sampson-Johannes A, Williams A, et al, ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997; 3: 639–45. [PUBMED], [INFOTRIEVE]
- Milas M, Yu D, Lang A, et al, Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 2000; 7: 422–9. [PUBMED], [INFOTRIEVE]
- Miyake H, Hara I, Hara S, et al, Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model. Urology. 2000; 56: 332–6. [PUBMED], [INFOTRIEVE]
- Portella G, Pacelli R, Libertini S, et al, ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 2003; 88: 5027–32. [PUBMED], [INFOTRIEVE]
- Geoerger B, Grill J, Opolon P, et al, Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer. 2003; 89: 577–84. [PUBMED], [INFOTRIEVE]
- Wadler S, Yu B, Tan J Y, et al, Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res. 2003; 9: 33–43. [PUBMED], [INFOTRIEVE]
- Ganly I, Kirn D, Eckhardt G, et al, A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000; 6: 798–806. [PUBMED], [INFOTRIEVE]
- Khuri F R, Nemunaitis J, Ganly I, et al, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6: 879–85. [PUBMED], [INFOTRIEVE]
- Makower D, Rozenblit A, Kaufman H, et al, Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res. 2003; 9: 693–702. [PUBMED], [INFOTRIEVE]
- Nemunaitis J, Ganly I, Khuri F, et al, Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 2000; 60: 6359–66. [PUBMED], [INFOTRIEVE]
- Nemunaitis J, Cunningham C, Tong A W, et al, Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 2003; 10: 341–52. [PUBMED], [INFOTRIEVE]
- Rudin C M, Cohen E E, Papadimitrakopoulou V A, et al, An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003; 21: 4546–52. [PUBMED], [INFOTRIEVE]
- Vasey P A, Shulman L N, Campos S, et al, Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002; 20: 1562–9. [PUBMED], [INFOTRIEVE]
- Bruning A, Kohler T, Quist S, et al, Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther. 2001; 12: 391–9. [PUBMED], [INFOTRIEVE]
- Zeimet A G, Muller-Holzner E, Schuler A, et al, Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. 2002; 9: 1093–100. [PUBMED], [INFOTRIEVE]
- Zeimet A G, Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol. 2003; 4: 415–22. [PUBMED], [INFOTRIEVE]
- Ries S J, Brandts C H, Chung A S, et al, Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000; 6: 1128–33. [PUBMED], [INFOTRIEVE]
- Edwards S J, Dix B R, Myers C J, et al, Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol. 2002; 76: 12483–90. [PUBMED], [INFOTRIEVE]
- Hall A R, Dix B R, O'Carroll S J, et al, p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med. 1998; 4: 1068–72. [PUBMED], [INFOTRIEVE]
- Hann B, Balmain A. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol. 2003; 77: 11588–95. [PUBMED], [INFOTRIEVE]
- Hsieh J L, Wu C L, Lee C H, et al, Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin Cancer Res. 2003; 9: 338–45. [PUBMED], [INFOTRIEVE]
- Bottger A, Bottger V, Sparks A, et al, Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997; 7: 860–9. [PUBMED], [INFOTRIEVE]
- Chene P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer. 2003; 3: 102–9. [PUBMED], [INFOTRIEVE]
- Vassilev L T, Vu B T, Graves B, et al, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844–8. [PUBMED], [INFOTRIEVE]
- Hainaut P, Mann K. Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal. 2001; 3: 611–23. [PUBMED], [INFOTRIEVE]
- Meplan C, Richard M J, Hainaut P. Redox signalling and transition metals in the control of the p53 pathway. Biochem Pharmacol. 2000; 59: 25–33. [PUBMED], [INFOTRIEVE]
- Gaiddon C, Moorthy N C, Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J. 1999; 18: 5609–21. [PUBMED], [INFOTRIEVE]
- Kramer D L, Vujcic S, Diegelman P, et al, Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. Biochem Soc Trans. 1998; 26: 609–14. [PUBMED], [INFOTRIEVE]
- Kramer D L, Vujcic S, Diegelman P, et al, Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 1999; 59: 1278–86. [PUBMED], [INFOTRIEVE]
- Ray R M, Zimmerman B J, McCormack S A, et al, Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. Am J Physiol. 1999; 276: C684–91. [PUBMED], [INFOTRIEVE]
- Capizzi R. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996; 23: 2–17. [PUBMED], [INFOTRIEVE]
- North S, El, Ghissassi F, Pluquet O, et al, The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene. 2000; 19: 1206–14. [PUBMED], [INFOTRIEVE]
- Maurici D, Monti P, Campomenosi P, et al, Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene. 2001; 20: 3533–40. [PUBMED], [INFOTRIEVE]
- Buschmann T, Potapova O, Bar-Shira A, et al, Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol. 2001; 21: 2743–54. [PUBMED], [INFOTRIEVE]
- Pluquet O, North S, Richard M J, et al, Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem Pharmacol. 2003; 65: 1129–37. [PUBMED], [INFOTRIEVE]
- Pluquet O, North S, Bhoumik A, et al, The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem. 2003; 278: 11879–87. [PUBMED], [INFOTRIEVE]
- Komarov P G, Komarova E A, Kondratov R V, et al, A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285: 1733–7. [PUBMED], [INFOTRIEVE]
- Culmsee C, Zhu X, Yu Q S, et al, A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem. 2001; 77: 220–8. [PUBMED], [INFOTRIEVE]
- Culmsee C, Siewe J, Junker V, et al, Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci. 2003; 23: 8586–95. [PUBMED], [INFOTRIEVE]
- Mattila K J, Valtonen V V, Nieminen M S, et al, Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis. 1998; 26: 719–34. [PUBMED], [INFOTRIEVE]
- Speir E, Modali R, Huang E S, et al, Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994; 265: 391–4. [PUBMED], [INFOTRIEVE]
- Komarova E A, Neznanov N, Komarov P G, et al, p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem. 2003; 278: 15465–8. [PUBMED], [INFOTRIEVE]
- Schafer T, Scheuer C, Roemer K, et al, Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. FASEB J. 2003; 17: 660–7. [PUBMED], [INFOTRIEVE]
- Vollmar B, El, Gibaly A M, Scheuer C, et al, Acceleration of cutaneous wound healing by transient p53 inhibition. Lab Invest. 2002; 82: 1063–71. [PUBMED], [INFOTRIEVE]
- Zhang M, Liu W, Ding D, et al, Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience. 2003; 120: 191–205. [PUBMED], [INFOTRIEVE]
- Rocha S, Campbell K J, Roche K C, et al, The p53-inhibitor Pifithrin-alpha inhibits Firefly Luciferase activity in vivo and in vitro. BMC Mol Biol. 2003; 4: 9, [PUBMED], [INFOTRIEVE]
- Milner J, Medcalf E A. Temperature-dependent switching between “wild-type” and “mutant” forms of p53-Val135. J Mol Biol. 1990; 216: 481–4. [PUBMED], [INFOTRIEVE]
- Zhang W, Guo X Y, Hu G Y, et al, A temperature-sensitive mutant of human p53. EMBO J. 1994; 13: 2535–44. [PUBMED], [INFOTRIEVE]
- Hupp T R, Meek D W, Midgley C A, et al, Regulation of the specific DNA binding function of p53. Cell. 1992; 71: 875–86. [PUBMED], [INFOTRIEVE]
- Abarzua P, LoSardo J E, Gubler M L, et al, Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 1995; 55: 3490–4. [PUBMED], [INFOTRIEVE]
- Kim A L, Raffo A J, Brandt-Rauf P W, et al, Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem. 1999; 274: 34924–31. [PUBMED], [INFOTRIEVE]
- Caron, de, Fromentel, Gruel N, Venot C, et al, Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 1999; 18: 551–7
- Govorko D, Cohen G, Solomon B. Single-chain antibody against the common epitope of mutant p53: Isolation and intracytosolic expression in mammalian cells. J Immunol Methods. 2001; 258: 169–81. [PUBMED], [INFOTRIEVE]
- Roth J, Lenz-Bauer C, Contente A, et al, Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res. 2003; 63: 3904–8. [PUBMED], [INFOTRIEVE]
- Foster B A, Coffey H A, Morin M J, et al, Pharmacological rescue of mutant p53 conformation and function. Science. 1999; 286: 2507–10. [PUBMED], [INFOTRIEVE]
- Friedler A, Hansson L O, Veprintsev D B, et al, A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA. 2002; 99: 937–42. [PUBMED], [INFOTRIEVE]
- Samuels-Lev Y, O'Connor D J, Bergamaschi D, et al, ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001; 8: 781–94. [PUBMED], [INFOTRIEVE]
- Friedler A, Veprintsev D B, Hansson L O, et al, Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules. J Biol Chem. 2003; 278: 24108–12. [PUBMED], [INFOTRIEVE]
- Issaeva N, Friedler A, Bozko P, et al, Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA. 2003; 100: 13303–7. [PUBMED], [INFOTRIEVE]
- O'Connor P M, Jackman J, Bae I, et al, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57: 4285–300. [PUBMED], [INFOTRIEVE]
- Weinstein J N, Myers T G, O'Connor P M, et al, An information-intensive approach to the molecular pharmacology of cancer. Science. 1997; 275: 343–9. [PUBMED], [INFOTRIEVE]
- Bykov V J, Issaeva N, Shilov A, et al, Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8: 282–8. [PUBMED], [INFOTRIEVE]
- Bykov V J, Issaeva N, Selivanova G, et al, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database. Carcinogenesis. 2002; 23: 2011–8. [PUBMED], [INFOTRIEVE]
- Caron, de, Fromentel, May-Levin F, Mouriesse H, et al, Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer. 1987; 39: 185–9
- Crawford L V, Pim D C, Bulbrook R D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982; 30: 403–8. [PUBMED], [INFOTRIEVE]
- Soussi T. p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 2000; 60: 1777–88. [PUBMED], [INFOTRIEVE]
- Lo Y M, Corbetta N, Chamberlain P F, et al, Presence of fetal DNA in maternal plasma and serum. Lancet. 1997; 350: 485–7. [PUBMED], [INFOTRIEVE]
- Anker P, Stroun M. Circulating DNA in plasma or serum. Medicina (B Aires). 2000; 60: 699–702
- Kopreski M S, Benko F A, Kwee C, et al, Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer. 1997; 76: 1293–9. [PUBMED], [INFOTRIEVE]
- Esteller M, Sanchez-Cespedes M, Rosell R, et al, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999; 59: 67–70. [PUBMED], [INFOTRIEVE]
- Chen X Q, Stroun M, Magnenat J L, et al, Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996; 2: 1033–5. [PUBMED], [INFOTRIEVE]
- Nawroz H, Koch W, Anker P, et al, Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996; 2: 1035–7. [PUBMED], [INFOTRIEVE]
- Gonzalez R, Silva J M, Sanchez A, et al, Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance. Ann Oncol. 2000; 11: 1097–104. [PUBMED], [INFOTRIEVE]
- Hibi K, Robinson C R, Booker S, et al, Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 1998; 58: 1405–7. [PUBMED], [INFOTRIEVE]
- Kirk G D, Camus-Randon A M, Mendy M, et al, Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst. 2000; 92: 148–53. [PUBMED], [INFOTRIEVE]
- Szymanska K, Lesi F, Kirk G D, et al, Ser-249 TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in The Gambia, West Africa. Int J Cancer. 2004
- Jackson P E, Kuang S Y, Wang J B, et al, Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis. 2003; 24: 1657–63. [PUBMED], [INFOTRIEVE]
- Lowe S W, Schmitt E M, Smith S W, et al, p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993; 362: 847–9. [PUBMED], [INFOTRIEVE]
- Marks D I, Kurz B W, Link M P, et al, High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood. 1996; 87: 1155–61. [PUBMED], [INFOTRIEVE]
- Berns E M, van, Staveren I L, Look M P, et al, Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 1998; 77: 1130–6. [PUBMED], [INFOTRIEVE]
- Borresen-Dale A L, Lothe R A, Meling G I, et al, TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res. 1998; 4: 203–10. [PUBMED], [INFOTRIEVE]
- Skaug V, Ryberg D, Kure E H, et al, p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res. 2000; 6: 1031–7. [PUBMED], [INFOTRIEVE]
- North S, Pluquet O, Maurici D, et al, Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog. 2002; 33: 181–8. [PUBMED], [INFOTRIEVE]
- Shi L M, Myers T G, Fan Y, et al, Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol. 1998; 53: 241–51. [PUBMED], [INFOTRIEVE]